
Heska Corporation HSKA
Quarterly report 2023-Q1
added 05-05-2023
Heska Corporation Book Value 2011-2026 | HSKA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Heska Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 422 M | 436 M | 287 M | 154 M | 122 M | 100 M | 87 M | 63.5 M | 53.1 M | 50.5 M | 48.9 M | 48.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 436 M | 48.4 M | 156 M |
Quarterly Book Value Heska Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 418 M | 422 M | 408 M | 417 M | 429 M | 436 M | 435 M | 434 M | 425 M | 287 M | 287 M | 287 M | 287 M | 155 M | 155 M | 155 M | 155 M | 122 M | 122 M | 122 M | 122 M | 100 M | 100 M | 100 M | 100 M | 87 M | 87 M | 87 M | 87 M | 79.3 M | 79.3 M | 79.3 M | 79.3 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 64.2 M | 64.2 M | 64.2 M | 64.2 M | 48.9 M | 48.9 M | 48.9 M | 48.9 M | 48.4 M | 48.4 M | 48.4 M | 48.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 436 M | 48.4 M | 165 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.65 | -1.84 % | $ 61.9 M | ||
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 115.55 | 1.0 % | $ 35.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 1.67 | -2.34 % | $ 2.22 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 24.46 | 3.25 % | $ 679 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 21.23 | 5.83 % | $ 1.13 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 84.33 | 1.82 % | $ 5.69 B | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 16.31 | 1.75 % | $ 493 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 410.54 | 4.35 % | $ 11.8 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 169.8 | 1.23 % | $ 8.42 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 88.91 | 1.18 % | $ 11.1 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.98 | -2.37 % | $ 8.76 M | ||
|
Illumina
ILMN
|
6.3 B | $ 127.88 | 1.95 % | $ 20.3 B | ||
|
National Research Corporation
NRC
|
14 M | $ 17.23 | -0.12 % | $ 386 M | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.47 | -0.58 % | $ 20 B | ||
|
Personalis
PSNL
|
203 M | $ 6.1 | 3.39 % | $ 361 M | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.14 | -0.47 % | $ 4.92 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 102.17 | -3.92 % | $ 8.43 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.8 | -0.43 % | $ 21.9 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Celcuity
CELC
|
101 M | $ 121.03 | 6.58 % | $ 5.66 B | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 469.71 | 0.64 % | $ 177 B | ||
|
NeoGenomics
NEO
|
837 M | $ 8.29 | 4.8 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.54 | 2.03 % | $ 2.07 B | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 60.94 | 3.55 % | $ 3.64 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.78 | -0.21 % | $ 443 M | ||
|
Natera
NTRA
|
706 M | $ 203.75 | 1.3 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 196.27 | -1.66 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | ||
|
Waters Corporation
WAT
|
2.56 B | $ 309.87 | -0.43 % | $ 18.5 B |